血管新生は高コレステロール血症によって低下する:非対称性ダイメチルアルギニンの役割
1Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305-5406, USA.
Circulation
|September 20, 2000
まとめ
高コレステロールは,酸化窒素 (NO) 合成酵素阻害剤である非対称性ダイメチルルギニン (ADMA) のレベルを増やすことにより,血管の成長 (血管新生) を妨げます. L-アルギニンを補充すると,この効果は逆転し,ADMAが確認されました.
科学分野:
- 心血管生物学 心血管生物学
- 内皮機能の機能について
- 血管生物学 血管生物学
背景:
- 内皮に由来する酸化窒素 (NO) は,多くの血管新生因子にとって極めて重要です.
- 非対称性ダイメチルアルギニン (ADMA) は,NO合成酵素の内生競争性アンタゴニストである.
- 高コレステロール血症は,ADMA濃度の上昇と関連しており,NO合成を減少させます.
研究 の 目的:
- 高コレステロール血症がADMA依存メカニズムを通じて血管新生を阻害するかどうかを調査する.
- 脂質誘発性血管新生機能不全におけるADMAの役割を決定する.
主な方法:
- 正常およびアポリポプロテインE欠乏症の高コレステロール血症のマウスで皮下ディスクインプラントシステムを使用して血管新生を評価した.
- アンジオゲネシスの指標として測定された線維血管成長.
- L-アルギニンまたはL-ニトロアルギニンを経口投与し,ADMAを直接ディスクに投与する.
主要な成果:
- 血管新生は,高コレステロール血症のマウスで低下し,血ADMAの上昇と相関していました.
- 口服によるL-アルギニンの投与は,高コレステロール血症のマウスの血管新生障害を逆転させた.
- ADMAは血管新生を直接抑制し,L-アルギニンが効果を逆転させた.
結論:
- 高コレステロール血症に関連したNO合成経路の乱れは,血管新生を損なう.
- ADMAは,血管新生の内生性阻害剤として関与しています.
- 研究結果は,ADMAが脂質誘発性血管新生障害を媒介することを示唆しており,L-アルギニンで逆行可能である.
さらに関連する動画
関連する概念動画
Regulation of Angiogenesis and Blood Supply
2.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Cholesterol: Significance and Regulation
2.1K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
2.1K
Coronary Artery Disease I: Introduction
1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741


